Is targeted radioisotope therapy done with lutetium-177?

Targeted radioisotope therapy combines a radioactive substance with a carrier molecule. The carrier is designed to bind to a marker on or near selected cancer cells. Lutetium-177 then releases radiation close to those cells, while the body clears the treatment through normal pathways. This is different from external-beam radiation, which directs radiation from a machine outside the body.

The treatment is considered only when testing and clinical assessment show that the relevant target is present and the treatment is suitable. Kidney function, blood counts, previous therapies, symptoms, and other health conditions can affect planning. Treatment is usually given as an intravenous infusion in a specialist setting, with monitoring and instructions about contact with others afterward.

Ask which scan or test confirms the target and whether you need to pause any medicines. Tell the team about kidney problems, blood disorders, pregnancy or breastfeeding, and previous radiation or chemotherapy. Follow instructions about fluids, medicines, eating, and visits. The team may check blood counts and kidney function before treatment and during follow-up.

You will receive practical radiation-safety guidance, such as how to handle body fluids and how to limit close contact for the period advised by your specialist. Do not improvise restrictions; ask the treatment centre if you are unsure.

Contact your treatment team for persistent vomiting, inability to drink, fever, unusual bruising or bleeding, marked weakness, reduced urine, or worsening pain after treatment. Seek urgent help for severe allergic symptoms, fainting, confusion, or difficulty breathing. Keep the centre's after-hours number with your treatment instructions.

What target does the carrier recognise in my cancer? How will kidney function and blood counts be monitored? What medicines should I take or avoid? What radiation-safety instructions apply at home, and which symptoms need urgent attention?